Rate My Professor Aniruddha Chatterjee

Chatterjee's research employs bioinformatics and experimental approaches to study epigenetic changes, particularly DNA methylation, in cancer metastasis, generating epigenetic maps for melanoma, oral, colorectal, lung, and prostate cancers. Additional interests include analytical tools for epigenomic analysis, cellular and tissue-specific epigenetics, environmental epigenetics, and recent work on myalgic encephalomyelitis/chronic fatigue syndrome and Long COVID. Key publications include 'Epigenetic drivers of tumourigenesis and cancer metastasis' (Seminars in Cancer Biology, 2018), 'Promoter DNA hypermethylation and paradoxical gene activation' (Trends in Cancer, 2020), 'Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy' (Trends in Immunology, 2019), and editorship of Epigenetics of Cervical Cancer (Springer, 2025). He developed the DMAP differential methylation analysis package (Bioinformatics, 2014). Awards include the Royal Society Te Apārangi Rutherford Discovery Fellowship (2017–2024), Health Research Council Sir Charles Hercus Health Research Fellowship, and Illumina Emerging Researcher Award (2015). Chatterjee teaches PATH 301 Applied Pathology, PATH 302 Cancer Pathology, BINF 701 Introduction to Clinical Bioinformatics, and GENE 412 Current Topics in Genetics. He holds executive roles in Genetics Otago, is New Zealand representative for the Australian Epigenetics Alliance, and contributes to committees like the Maurice Wilkins Centre and Melanoma Network of New Zealand. His work has significant impact, with high citation counts and global recognition, including ranking in the top 0.05% of scientists worldwide.